Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
864.63
+5.20 (+0.61%)
Streaming Delayed Price
Updated: 1:05 PM EDT, Jul 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about argenx SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
↗
June 12, 2026
Executives at argenex (NASDAQ:ARGX) told investors at a Goldman Sachs healthcare event that they continue to see meaningful growth opportunities for VYVGART across myasthenia gravis and chronic...
Via
MarketBeat
Topics
Intellectual Property
Supply Chain
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
↗
June 05, 2026
argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth,...
Via
MarketBeat
Topics
Intellectual Property
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
↗
May 29, 2026
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
↗
May 29, 2026
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
Via
The Motley Fool
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
↗
May 16, 2026
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
Via
The Motley Fool
2 Ways to Play the Big Pharma Patent Cliff
↗
May 15, 2026
With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.
Via
MarketBeat
Topics
ETFs
Intellectual Property
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
↗
March 21, 2026
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
↗
March 21, 2026
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
Via
The Motley Fool
Topics
Regulatory Compliance
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
↗
March 20, 2026
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Via
The Motley Fool
Topics
Regulatory Compliance
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...
Via
Finterra
Topics
Economy
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch
↗
March 09, 2026
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of...
Via
Stocktwits
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
February 26, 2026
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
↗
February 17, 2026
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
↗
February 17, 2026
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake
↗
February 17, 2026
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Via
The Motley Fool
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More
↗
February 17, 2026
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Via
The Motley Fool
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...
Via
Finterra
Topics
ETFs
Economy
Initial Public Offering
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
January 02, 2026
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
December 31, 2025
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
December 26, 2025
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...
Via
PredictStreet
Topics
Economy
Intellectual Property
ARGENX SE (NASDAQ:ARGX) Combines Minervini Trend Strength with Explosive Fundamental Growth
↗
December 01, 2025
ARGENX (ARGX) stock combines strong technical trends with explosive fundamental growth in EPS and sales, making it a high-momentum candidate for investors.
Via
Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 19, 2025
Via
Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
↗
November 18, 2025
Via
Benzinga
Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules
↗
November 14, 2025
Argenx SE fits a proven growth stock strategy, showing explosive earnings and sales growth, widening margins, and strong cash flow.
Via
Chartmill
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
↗
November 05, 2025
Via
Benzinga
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports
↗
October 30, 2025
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.
Via
Investor's Business Daily
ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria
↗
October 24, 2025
Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria.
Via
Chartmill
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
↗
October 22, 2025
Via
Benzinga
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks
↗
October 22, 2025
Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers offer up three stocks that face dark clouds they can see through.
Via
The Motley Fool
Topics
Workforce
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
